147 related articles for article (PubMed ID: 12650515)
1. PAS inclusions, immunoreactive tenascin and proliferative activity in low-grade chondrosarcomas.
Ranty ML; Michot C; Le Pessot F; Hellot MF; Biga N; Dujardin FH; Simonet J; Billerey C; Metayer J
Pathol Res Pract; 2003; 199(1):29-34. PubMed ID: 12650515
[TBL] [Abstract][Full Text] [Related]
2. Differentiation and proliferative activity in benign and malignant cartilage tumors of bone.
Hasegawa T; Seki K; Yang P; Hirose T; Hizawa K; Wada T; Wakabayashi J
Hum Pathol; 1995 Aug; 26(8):838-45. PubMed ID: 7543439
[TBL] [Abstract][Full Text] [Related]
3. Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors.
Helfenstein A; Frahm SO; Krams M; Drescher W; Parwaresch R; Hassenpflug J
Am J Clin Pathol; 2004 Dec; 122(6):912-8. PubMed ID: 15539383
[TBL] [Abstract][Full Text] [Related]
4. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas.
Grifone TJ; Haupt HM; Podolski V; Brooks JJ
Int J Surg Pathol; 2008 Jan; 16(1):31-7. PubMed ID: 18203781
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
[TBL] [Abstract][Full Text] [Related]
8. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors.
Eefting D; Schrage YM; Geirnaerdt MJ; Le Cessie S; Taminiau AH; Bovée JV; Hogendoorn PC;
Am J Surg Pathol; 2009 Jan; 33(1):50-7. PubMed ID: 18852676
[TBL] [Abstract][Full Text] [Related]
9. Expression of leukemia inhibitory factor by cartilage-forming tumors of bone: an immunohistochemical study.
Gouin F; Moreau A; Couillaud S; Guicheux J; Passuti N; Godard A; Heymann D
J Orthop Res; 1999 Mar; 17(2):301-5. PubMed ID: 10221849
[TBL] [Abstract][Full Text] [Related]
10. Enchondroma vs. chondrosarcoma: a simple, easy-to-use, new magnetic resonance sign.
Vanel D; Kreshak J; Larousserie F; Alberghini M; Mirra J; De Paolis M; Picci P
Eur J Radiol; 2013 Dec; 82(12):2154-60. PubMed ID: 22227263
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
[TBL] [Abstract][Full Text] [Related]
12. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.
Rozeman LB; Hameetman L; van Wezel T; Taminiau AH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
J Pathol; 2005 Sep; 207(1):61-71. PubMed ID: 16007578
[TBL] [Abstract][Full Text] [Related]
13. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
Rozeman LB; Hameetman L; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Pathol; 2005 Mar; 205(4):476-82. PubMed ID: 15685701
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
[TBL] [Abstract][Full Text] [Related]
15. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
Huse JT; Pasha TL; Zhang PJ
Acta Neuropathol; 2007 Jan; 113(1):87-94. PubMed ID: 17021752
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
Masi L; Malentacchi C; Campanacci D; Franchi A
Virchows Arch; 2002 May; 440(5):491-7. PubMed ID: 12021923
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.
Kalinski T; Sel S; Kouznetsova I; Röpke M; Roessner A
Pathol Res Pract; 2009; 205(5):339-45. PubMed ID: 19157720
[TBL] [Abstract][Full Text] [Related]
18. Chondrosarcoma is not characterized by detectable telomerase activity.
Bovée JV; van Den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2001 Mar; 193(3):354-60. PubMed ID: 11241416
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas.
Aigner T; Müller S; Neureiter D; Illstrup DM; Kirchner T; Björnsson J
Cancer; 2002 Apr; 94(8):2273-81. PubMed ID: 12001127
[TBL] [Abstract][Full Text] [Related]
20. Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma.
Shooshtarizadeh T; Nazeri A; Zare-Mirzaie A; Movahedinia S
Pathol Res Pract; 2016 Apr; 212(4):335-9. PubMed ID: 26948096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]